Lundbeckfonden Ventures Portfolio

Acacia Pharma is a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy.

Akamis Bio is an oncolytic virus drug development company whose proprietary T-SIGn virus platform enables intravenous delivery of payload carrying oncolytic viruses.

Stem cell treatment for Acute Kidney Injury. Developed AC607, an off-the shelf treatment based on Mesenchymal Stem Cells

Amplyx Pharmaceuticals develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.

Asante Solutions, Inc. developed an easy-to-use, disposable insulin pump that was affordable, reliable, and had strong appeal to patients in terms of user friendliness and physical appearance.

Atox Bio is a critical care immunotherapy company focusing on acute life-threatening conditions with significant unmet medical need.

Aura Biosciences is a biopharmaceutical company aiming to transform the treatment of early-stage tumours to prevent metastasis and improve outcomes for patients with cancer.

Biom’Up develops and commercializes hemostatic products based on patented biopolymer designed to simplify surgeons’ practices for open surgical procedures in numerous specialties such as cardiac, general, orthopedic, and laparoscopic surgeries.

BONESUPPORT has a platform for delivering drugs to bone using CERAMENT™ - IPO in 2017 – BONEX (Nasdaq Stockholm).

Was in phase II/III trial with a SERCa2a gene therapy to help heart failure patients hearts to beat without increasing their oxygen consumption.

Curzion was developing a compound for Diffuse cutaneous systemic sclerosis (dcSSc), a rare, chronic autoimmune disease marked by fibrosis, or skin thickening, in areas including hands, forearms, upper arms and thighs.

Cydan Development is the first orphan drug accelerator dedicated to advancing therapies that improve the lives of patients with rare genetic diseases.

Develops patches for desensitization of food allergy using epicutaneous delivery. The lead program is in late stage clinical trials for peanut allergy desensitization.

DYSIS Medical is a medical technology commercialization company that provides clinicians with a high-resolution digital Smart Colposcope to help with the identification of the most relevant biopsy sites when cancerous and pre-cancerous cervical cancer lesions are suspected.

Enliven Therapeutics is developing a novel, chronic, oral treatment for patients with sickle cell disease and other haemoglobinopathies.

Enterome is pioneering the development of novel microbiome based drugs to treat cancer and GI track related disorders.

Discovery of new pharmaceuticals for the treatment of cancer within the field of epigenetics.

Iconic Therapeutics targets Tissue Factor (TF) in angiogenesis, inflammation, cell growth and metastasis to treat ophthalmologic, oncologic, and autoimmune diseases.

Lexeo Therapautics is a gene-therapy biotechnology company developing treatments for genetically defined cardiovascular and central nervous system diseases.

Nexstim offers navigated brain stimulation solutions which help diagnose and treat challenging brain diseases and disorders with confidence.

Reneo Pharmaceuticals is a pharmaceutical company that specializes in discovering and developing therapies for rare and potentially life-threatening genetic mitochondrial diseases including Primary Mitochondrial Myopathies (PMMs), Fatty Acid Oxidation Disorders (FAODs) and McArdle disease.

Developed a biologic to treat the orphan eye disorder Graves Orbitopathy, a very debilitating condition that ultimately can lead to blindness.

Sanifit is a drug development company that is developing treatments for calcification disorders where hydroxyapatite (HAP) crystals form and grow in blood vessels, leading to stiffer and narrower arteries.

scPharmaceuticals provides subcutaneous administration of therapies that have previously been limited to intravenous, or IV, delivery reducing overall healthcare costs and advances the quality and convenience of care.

Spero has a pipeline of novel treatments for multi-drug resistant (MDR) bacterial infections.

Syntaxin developed bacterial-based protein therapeutics that inhibit cell secretion for the treatment of neurological, inflammatory and endocrine diseases.

Thesan Pharmaceuticals developed novel therapeutics for disorders of the skin.

Tiburio Therapeutics is a drug development company that develops novel small molecule treatments for potentially life-threatening rare neuroendocrine tumours and endocrine diseases such as non-functioning pituitary adenoma (NFPA).

Trevi Therapeutics develops Nalbuphine® ER for chronic pruritus (itch).

VarmX is a drug development company, developing drugs to restore haemostasis in case of bleeding or emergency surgery in patients taking oral factor Xa inhibitors.

Veloxis has developed Envarsus® XR (once daily tacrolimus extended-release tablets) based upon the company’s delivery technology, MeltDose®.

VHsquared has developed a platform of oral biologics – Vorabodies™ – for inflammatory bowel disease.

Developed VTS-270 to treat patients with Niemann-Pick Disease Type C.

Developed dermatological drugs, the lead being an H4 receptor antagonist tested in Atopic Dermatitis and Psoriasis patients.